BIOINNOVATE - Key Persons
Job Titles:
- Fellowship Programme Manager
Alice created a niche for herself after completing the 2016/2017 BioInnovate process and is now Health and LifeSciences Innovation Manager at Accenture working at The Dock Innovation Centre in Dublin. The Dock is a design-led, multidisciplinary research and incubation hub where Alice interacts with global clients to transform their business through advanced analytics, artificial intelligence, IoT, blockchain and mixed reality. Her key focus is helping her Health & Life Sciences clients to harness innovative technology to improve healthcare. She has encompassed the BioInnovate model into her approach within the progressive global consultancy company and is looking forward to implementing structures around developing new healthcare innovations in the future.
Andrew, upon completion of the 2015/16 BioInnovate fellowship, continued to grow his healthcare consultancy company, Situla Consulting, which he set up with 2012/13 BioInnovate fellow Caroline Gaynor (now Vice President of Lightstone Ventures). In 2016 and 2017, he leveraged his significant and well established commercial acumen to complete consultancy assignments for a number of diverse international clients including Dolmen, One Projects (cofounded by his BioInnovate peers Fionn Lahart and Christoph Hennersperger) and EIT Health. A true advocate of the BioDesign process, Andrew recently completed substantial consultancy projects for NUI Galway based innovation centres CURAM, BioXL and BioInnovate before assuming the role of Director of Innovation Development with i360medical, a Dublin and New York based company devoted to accelerating hospital based innovations.
Annette Kent, BioInnovate Fellow 2015/16 and member of the Cardiothoracics team based in St James's Hospital, Dublin, is now Clinical Director with FIRE1. The company, headquartered in Dublin, is supported by The Foundry in California whose key focus is creating novel connected medical solutions dedicated to improving outcomes for people suffering with chronic disease. FIRE1's first product is an innovative monitoring solution to improve outcomes for Heart Failure patients. As Clinical Director, Annette is responsible for the development and implementation of the FIRE1 clinical programme, working very closely with key stakeholders, clinicians, advisors and trial sites. FIRE1 closed its Series C financing totalling 40 million in January 2018.
Ashwin has worked on a number of projects since 2013 and is now Currently Director of Emedtx, a company established in January 2015.
Working closely with BioInnovate teammate David Townley, Brian cofounded and is CEO of Neurent Medical, a company developing a novel office-based treatment for Rhinitis, a condition affecting millions of people globally. The duo continued to de-risk the project during a 2-year period, utilising the Enterprise Ireland Commercialisation Fund mechanism and recently closed a Series A round of investment of 9.3 million to progress the project towards CE mark and FDA approval, and commercialisation.
Job Titles:
- Member of the Advisory Board
- Partner, Lightstone Ventures
Caroline became Commercial Lead of Vetex Medical towards the end of the 2012/2013 BioInnovate semester (working alongside BioInnovate co-founder Mark Bruzzi) while also becoming Director at Situla Consulting, a company established to create commercial strategies for MedTech companies (from SMEs to University based engineering departments and spinouts to Large MNCs). She subsequently moved to Lightstone Ventures and is currently the company's Vice President, a role she has enjoyed since September 2016.
Job Titles:
- Fellow from the 2011 / 2012
Cassandra, a Whitaker Fellow from the 2011/2012 BioInnovate program used the expertise she acquired from the 10-month process to educate others. From 2014 to 2016, she acted as a BioDesign Process Instructor in University of Colorado Springs and since then is viewed as an eminent BioDesign expert now employed by University of Colorado Denver.
As a member of the Cork based BioInnovate team in 2014/15, Christopher continues to innovate within a number of projects based in the United States.
Colin Forde, along with his fellow BioInnovate colleagues Wayne Allen and Liam Mullins uncovered an unmet, underserved clinical need to embolise patients reliably in one shot. Stemming from this, they successfully applied for Enterprise Ireland Commercialisation Funding to de risk the project for Series A investment. In 2014, after spinning out from National University of Ireland Galway to form Embo Medical, the team obtained a further 3 million in funding from Enterprise Ireland and AIB's Seed Capital Fund. Subsequently in 2016, Embo Medical was acquired by CR Bard's subsidiary Clearstream for almost 43.5 million. Following the acquisition completion, Colin is working on a number of new projects in the Medtech space.
Colm, following the 2015 BioInnovate program, cofounded Selio Medical with his teammate Garrett Ryan, a company which continues to develop a novel medical device to prevent pneumothorax during transthoracic needle biopsy. Utilising the Enterprise Ireland Commercialisation Fund mechanism to achieve substantial seed funding, the company has strived to accelerate its technology to market. As CEO, Colm has worked closely with Garrett (CTO) to leverage a number of incubating agencies including the prestigious National Science Foundation I-corps Accelerator Program in Georgia Tech, Atlanta and the industry leading Medtech Innovator Accelerator in San Francisco where they successfully achieved third place out of 600 entries. Selio Medical will spin out from Trinity College Dublin in late-2018 and are currently seeking a Series A investment of 2.5million to bring the technology to First in Human clinical trials in 2019.
Conor continues to fly the flag for BioInnovate and used his time in the fellowship to cultivate an unmet need in Benign Prostatic Hyperplasia, which affects millions of men globally as they age. While awaiting investment from Enterprise Ireland's Commercialisation Fund, Conor worked from June to October 2013 as an Investment Analyst/Advisor for Venture Capital firm Seroba Lifesciences. Upon award of an Enterprise Ireland grant, he became co-founder and CEO of ProVerum Medical until August 2017 and is now Chief Scientific Officer of the BioInnovate spin-out startup. He has won numerous awards and has received substantial Series A funding, which has facilitated the company to continue to develop Conor's novel, universal solution for BPH.
Damien was a member of the team who began immersion in Mayo Clinic, a global centre of healthcare excellence, which facilitated for the first time ever a BioInnovate team to go to its base in Rochester, Minnesota and uncover unmet clinical needs. Damien worked closely with the clinical staff there and discovered a need within the biopsy space.
From this experience, Damien is now CTO of EndoCore Ltd, a BioInnovate spinout which has solved the challenge of taking a core tissue biopsy through tortuous anatomy. EndoCore's technology is initially targeting the endoscopic ultrasound market and has wider platform potential including applications in the lung and liver. EndoCore has developed its technology with grant assistance and equity investment from Enterprise Ireland and is currently seeking additional funding in order to obtain 510k approval in 2019.
David, upon completion of BioInnovate in 2013 worked until mid-2015 as Incereb Product Manager focussing on product development. In 2015 he moved to a position in the Irish Development Authority (IDA) as Technology and Information Advisor (Lifesciences, Business Development Manager) and subsequently was promoted to IDA Ireland's Vice President, based in Orange County, California where he works with Tech companies on the US West Coast, helping them to leverage Ireland for international growth. David continues to act as a true ambassador and advocate of the BioInnovate program.
Job Titles:
- Member of the Advisory Board
- Director, Innovation Office, University of Galway
Adrian completed the BioInnovate program in the summer of 2016 and immediately returned to clinical practice. He is on the General Practitioner Scheme (currently based in Our Lady's Hospital, Drogheda) with the aim of completing his GP specialist training in the coming years. His ambition is to re-engage with concepts he was developing as part of his time in BioInnovate upon completion of his training scheme.
Following BioInnovate, James returned to clinical medicine. Between 2012-2016 he trained as a Specialist Registrar in Radiology in Beaumont Hospital, Dublin and since July 2017 was promoted to Consultant Muscloskeletal Radiologist where he currently resides in Oxford University Hospital. He continues to identify unmet clinical needs in the NHS and utilises the Oxford BioDesign program to support continued innovation in the field.
Following the 2015/16 BioInnovate program, John partnered up with fellow graduate Tony O'Halloran to create Aurigen Medical, a company devoted to developing a novel cardiac implant technology to treat persistent Atrial Fibrillation. Upon award of an Enterprise Ireland Commercialisation Fund Grant in 2016, the duo's work has received significant international attention, winning the 2017 EIT Headstart Award and being selected to present at the prestigious EuroPCR Innovators Day in May 2018 in Paris. Aurigen Medical intends to spinout from National University of Ireland, Galway by the end of 2018, with a first in human trial scheduled for 2020. Aurigen also recently placed first out of 1,280 companies to win a 2.5million SME Instrument funding grant from EU's Horizon2020 to help the company quickly scale its novel innovation.
Dr Halligan was an integral part of his BioInnovate team during the 2013/2014 fellowship term. Following this, he was invited to become a Medical Resident in Lahey Hospital & Medical Center in Boston and since July 2017 is a Pulmonary & Critical Care Fellow in Umass Memorial Medical Center in Boston. Kyle continues to identify unmet clinical needs in the hospital environment.
Dr Azis continued his formidable career in medicine following his BioInnovate experience. From 2012 to present he has continued along his track towards medical consultancy as a Cardiology Specialist Registrar. He has trained in such prestigious hospitals as Royal Surrey County Hospital, Ashford and St Peter's Hospital, Guy's and St Thomas' and since 2016 has been a resident in King's College, London.
Alison completed the BioInnovate Fellowship 2015/16. By applying the Bioinnovate needs driven process Alison co-secured an Enterprise Ireland commercialisation fund. Alison subsequently along with a team from NUIGalway was awarded SFI funding as part of the SFI Innovator Prize to further the development of a patent protected technology for Chronic Pain. Alison will continue advancing the development and commercialisation of this technology.
Dr Andrew Cameron is currently the Project Lead of an Enterprise Ireland Commercialisation Fund project housed within NUI Galway. He and his team of engineers, academics, clinical experts, and commercial consultants are developing an adjustable compression device that measures and monitors sub-bandage pressure for the treatment of venous leg ulcers (VLUs), which he has termed "Tight Alright".
The project commenced in January 2018 and is expected to culminate in a healthy volunteer study of a prototype device at the end of 2019, at which point a start-up company (FeelTect) will be formed. Andrew's project is a direct outcome of the BioInnovate Ireland programme, where the underlying need was first identified during clinical immersion in the University Hospital Galway and the Mayo Clinic, Rochester. Furthermore, the learnings and networks that were established within the programme will continue to support the successful progression of the "Tight Alright" technology towards commercialisation and into the future
Dr Barry McDermott is the CTO of Relevium Medical, a successful spinout of NUI Galway and a direct product of the Bioinnovate programme. Barry has nearly 20 years' experience in the pharmaceutical and medical device sectors. He is an expert in both pharmaceutical and medical device development - and was selected as one of Ireland's representatives on the European Commission Expert Panel on Medical Devices. He is also a Member of the Pharmaceutical Society of Ireland. Barry has professional qualifications in Pharmacy, Veterinary Medicine, Engineering, and holds a Ph.D. in Biomedical Engineering. Initially Barry studied Pharmacy at TCD, giving a rigorous scientific training with emphasis on academic and industrial pharmaceutical skills. Studying Veterinary Medicine at UCD resulted in a thorough medical training, and a detailed understanding and appreciation of biomedical science. Finally Engineering (NUIG) has resulted in the necessary skills to develop solutions for real clinical needs. He has developed proposals that have secured > 3.5 Mn in peer-reviewed funding schemes, with > 25 publications, > 4 International Research/ Professional Recognition awards, and 4 patents.
Since Brendan's time in in BioInnovate, he has become CEO and Co-founder of Loci Orthopaedics Ltd, a company dedicated to developing a novel orthopaedic implant for the surgical treatment of thumb base joint arthritis. To date the company has secured seed round funding through the Enterprise Ireland Commercialisation Fund. Working with his BioInnovate teammate, Gerry Clarke, the company has amassed the following accolades: EIT Health UK-Ireland Headstart Winner; Medtec Ireland Start-up Contest Winner; Emerging Medtech Company of the Year Finalist 2017 Irish Medtech Awards; and County, Regional, and National Winner of Ireland's Best Young Entrepreneur Competition - Best Business Idea 2018. Loci Orthopaedics is aiming for regulatory clearance, clinical use, and commercialisation by 2020. The company is also developing its pipeline of products and building its IP portfolio and was recently awarded 2.75 million in a Series A funding round to achieve its development and commercial milestones.
Job Titles:
- Lecturer and Researcher, Electrical and Electronic Engineering, University of Galway
Conor, upon completion of the BioInnovate fellowship returned to clinical medicine, becoming a General Practitioner in Kiltimagh, Co. Mayo. He also became a chapter co-founder of Health 2.0 Galway which promotes IT health innovations in medical practice. Conor continues to support innovation in the healthcare sector, as he is passionate about patient centric care.
Job Titles:
- Consultant Nephrologist, Galway University Hospital
Cyrus, a true advocate of the BioInnovate process, continues to innovate utilising the BioDesign model. He is currently a contractor for Boston Scientific. However, he is also a Lead Project Manager in Trinity College Dublin, working on some exciting projects including a novel wound closure device, which obtained Enterprise Ireland Commercialisation Funding to de-risk the project towards Series A investment.
Job Titles:
- SFI Royal Society University Research Fellow and Assistant Professor, Biomedical Engineering, NUIG
- SFI Royal Society University Research Fellow and Assistant Professor, Biomedical Engineering, University of Galway
Dr. Eimear Dolan is a Science Foundation Ireland Royal Society University Research Fellow and Assistant Professor in Biomedical Engineering at NUI Galway. She completed her undergraduate and PhD degrees at NUI Galway and has worked as a postdoctoral researcher at Trinity College Dublin, the Royal College of Surgeons Ireland, NUI Galway and Massachusetts Institute of Technology. Her research focuses on developing next generation medical devices and her key interest is in implantable devices, their effect on the host cells and coupling advanced therapies to minimally invasive delivery devices.
Dr Dolan has received funding from national and international sources and has received awards for research excellence. Notably, she was awarded the 2020 NUI Galway President's Awards for Research Excellence (Early Stage Researcher) and was listed by MIT Technology Review 2020 "35 Innovators under 35" and one of 10 global visionaries. She has published in prestigious journals and has submitted invention disclosures and patents on innovations in medical device technology.
Job Titles:
- Senior Post - Doctoral Researcher
Dr. Eoghan Dunne is a Senior Post-Doctoral Researcher in the Translational Medical Device Lab and School of Engineering at the University of Galway as well as a honorary adjunct lecturer at the School of Medicine. He received a BEng in Electronic & Computer Engineering (2016) and Ph. D in Electrical and Electronic Engineering (2021) from University of Galway. His Ph. D was focused on using Machine Learning and Electrical Impedance Tomography for monitoring bladder fullness, during which he collaborated closely with the start up Kite Medical. Since in his Ph. D, he has been working on and with Government of Ireland Disruptive Technologies Innovation Fund (DTIF) funded projects to help design new innovate medical device solutions including: pulsed field ablation devices to treat Atrial Fibrillation (AuriGen Medical); ablation monitoring systems for lung cancer (Endowave Medical) and device enhancements for CTO crossings (Versono Medical). As well as fundamental science, his research focuses on translating research to deployable medical devices and he works closely with current and former BioInnovate fellows to translate their needs to concepts and prototypes.
Job Titles:
- Member of the Advisory Board
- Senior Vice President, Regulatory Affairs and Quality Assurance
Ian Purdy, Ph.D., is Intuitive's senior vice president, regulatory affairs and quality assurance. Dr. Purdy has more than 25 years of international quality, regulatory, and clinical research experience within large, global medical device and diagnostic companies. He has extensive experience in all classes of medical devices, diagnostics, equipment, and software and knowledge of AI/ML and integrated digital solutions.
Before joining Intuitive in 2022, Purdy was head of international and clinical affairs and compliance at Apple. Prior to that, he was senior vice president of quality assurance and regulatory affairs at Haemonetics. He also spent several years at Thermo Fisher Scientific as vice president of clinical, regulatory, and quality compliance. Purdy started his career at Smith Medical as a clinical research associate and scientific affairs officer, followed by 15 years at Boston Scientific in Europe and the U.S., where he worked across clinical research, regulatory affairs, and quality and rose to vice president, global quality systems.
Purdy has a Ph.D. in human physiology from Southampton University, UK, and a BSc. in applied and human biology from Aston University UK. He holds an advanced certificate for executives in management innovation and technology from MIT Sloan school of business.
Job Titles:
- Member of the Advisory Board
- Associate Director, Innovation Office, University of Galway
Job Titles:
- Member of the Advisory Board
- CEO, Palliare
Job Titles:
- Lecturer and Researcher, Medicine, University of Galway
Job Titles:
- Member of the Advisory Board
- Commercialisation Specialist and Relationship Manager, Enterprise Ireland
Nigel completed the BioInnovate fellowship in 2017. From his experience on the program, he partnered with his colleagues Sean Cummins and Stephen Cox to create Venari Medical, a medical device manufacturing company focusing on scientific research & development for better patient outcomes in venous disease. Having successfully gained Commercialisation Funding from Enterprise Ireland, the team were awarded first prize at the EIT Health Innovation Fellowship Alumni Showcase 2017. Venari Medical are continuing to develop the world's safest treatment for varicose veins, with Nigel as CMO. With pre-clinical trials close to completion, the company's ambition is to obtain Series A funding in 2019 to facilitate first-in-man clinical trials towards EU & US regulatory approval, and the commercialisation of the novel varicose vein treatment solution by 2020.
Upon completion of the 2014/15 BioInnovate fellowship, Peter opted to return to clinical medicine. He is currently successfully navigating a Specialist Registrar Scheme in Trauma and Orthopaedic Surgery. Peter continues to analyse the clinical environment in search of unmet needs.
Elizabeth, since the completion of the 2015/16 BioInnovate term, has continued to work closely with fellow Mayo Clinic teammate, Rory O'Callaghan, to innovate within the otology space. Elizabeth has also focussed on a clinical path towards consultancy, currently a member of the Specialist Registrar Scheme in Anaesthesia based in University Hospital, Galway with a recent move to University Hospital Limerick.
Job Titles:
- Member of the Advisory Board
- Director of Commercialisation, Enterprise Ireland
Job Titles:
- Member of the Advisory Board
- Director of Irish Medtech Association
Eoin, in conjunction with BioInnovate team mate, Moshe Zilversmit, co-founded Signum Surgical, a start-up whose key focus is developing novel minimally invasive technologies to treat colorectal diseases. The company has raised over 3 million to date with initial seed funding from the Enterprise Ireland Commercialisation Fund followed by Series A funding from a myriad of investment parties including Chip Hance (former CEO of Creganna), Medtech Syndicate Nominee, Switzerland based Glanzmann Enterprises, Rising Tide Europe 1, the Western Development Commission and Enterprise Ireland. Eoin and Moshe continue to build their IP portfolio and aim to commercialise their platform device in 2019.
Following the 2015/16 BioInnovate program, Fergal created Capri Medical, a company devoted to developing an injectable neurostimulation platform for chronic pain and various other neurological indications. The company leveraged seed funding from the Enterprise Ireland Commercialisation Fund to develop prototype devices and initial preclinical studies. Building on this success, in 2020 Capri Medical was awarded 2nd place in Europe's flagship EIC program and a 2.5million grant helped the company scale its team and IP. In 2022 the company was again successful in winning an additional 2m grant funding within a 6.5m EC Horizon project to begin First in Human studies.
Job Titles:
- CEO of VERSONO Medical Ltd
Finbar is currently CEO of VERSONO Medical Ltd., a Med Tech start-up company focused on commercialising a disruptive medical device platform technology to address a well understood unmet clinical need in the highest growth segment of the $10bn peripheral endovascular device market. Finbar further expanded his capabilities during the BioInnovate program to evaluate the viability of this novel Innovation.
Job Titles:
- Member of the Advisory Board
- Chairman of the BioInnovate Advisory Board and VP for Research and Development, Medtronic
Job Titles:
- Member of the Advisory Board
- Commercialisation Executive, Innovation Office, University of Galway
Job Titles:
- Member of the Advisory Board
- Executive Chairman & CEO at S3 Connected Health
- Executive Chairman and Chief Executive Officer of S3 Connected He
John began his career in the semiconductor industry and held various positions in technology, marketing, and engineering before becoming CEO of S3 Group in 2001.
In 2006 he led a management buyout of S3 Group from Philips. The buyout was financed by ACT Venture Capital. This funding was used to accelerate and develop S3 Group's activities in Healthcare, Semiconductors and Digital TV. In 2015 the S3 TV Technology business was acquired by Accenture and in 2018 the S3 Semiconductors business was acquired by Adesto Technologies.
He is currently Executive Chairman and CEO of S3 Connected Health, an active member of the Irish Software CEO Forum and was the 2020 Chairman of Irish Medtech
John has an engineering degree from the University of Limerick, an MBA from University College Dublin and has completed the Enterprise Ireland Leadership for Growth program at Stanford University.
Job Titles:
- Member of the Advisory Board
- General Partner, ACT Venture Capital
Job Titles:
- Member of the Advisory Board
- CEO, Endowave Ltd.
Job Titles:
- Member of the Advisory Board
- VP of Medical Technologies for US Mid - West, IDA Ireland Life Sciences Division
Job Titles:
- Member of the Advisory Board
- Medical Device Entrepreneur
A Medical Device Entrepreneur, Paul has raised > 150 million of VC and Corporate funds in UK, US, EU and Ireland. He has successfully co-founded and exited three start-up companies Co-founder and CSO at Novate Medical, a Galway based medical device company developing IVC filter technology recently acquired by BTG Medical.
He also co-founded Veryan Medical, an Imperial College London spin-out that was acquired in 2018 by Otsuka Medical Devices.
Previously, he was a co-founder and General Manager of MedNova and was responsible for the development of novel stroke treatment technologies. The Company was acquired by Abbott Laboratories in 2006. In addition, Paul was Chairman of Embo Medical a spinout from the NUIG / Stanford BioInnovate Programme, which was acquired by C.R. BARD in 2015. Prior to his experience in start-up companies he held a number of senior roles in Operations and R&D. He was Director of R&D for Bard Cardiology where he led the development of numerous cardiovascular devices.
He currently holds Board/Chairman roles at a number of Medtech start-ups, Bluedrop, Selio Medical, Ostoform, InVera Medical, Kite Medical and Proverum.
Paul has extensive experience in licensing and IP portfolio management and is the holder of more than 60 US patents for biomaterials and cardiovascular products.
Job Titles:
- Member of the Advisory Board
Job Titles:
- Consultant Surgeon, University of Galway and Galway University Hospital
Job Titles:
- Member of the Steering Committee
- Non - Executive Director
- Clinical Director and Advisory Board Member for BioInnovate Ireland
- Professor in Translational Cardiovascular Medicine and Innovation at NUI
Prof Faisal Sharif is Professor in Translational Cardiovascular Medicine and Innovation at NUI, Galway and a consultant Interventional Cardiologist for Galway University Hospitals. His research focuses on medical devices for cardiovascular medicine and translational research on vascular biology and myocardial regeneration.
Prof Sharif's has established strong industrial-clinical partnership with incorporation of novel medical devices including optical coherence tomography, renal artery denervation and transcatheter aortic valve implantation. He was the Principal Investigator for multinational randomised clinical trial involving autologous stem cell injection in patients with heart failure. Prof Sharif also continues to pursue research on vascular wall healing post-stenting through development of novel techniques and devices. His research focuses on developing novel solutions for unmet clinical needs for cardiovascular medicine. Prof Sharif's key area of interest is translational medicine focusing on cardiovascular clinical trials for medical devices and basic science outputs. Prof Sharif has been inducted as a Fellow to the Royal College of Physicians Ireland (FRCPI), the European Society of Cardiology (FESC), the American College of Cardiology (FACC). He is the Associate Director for Clinical Research facility Galway for cardiovascular trials.
Prof Sharif has authored over 20 peer-reviewed articles, filed three invention disclosures and holds two patents. He has also coordinated two clinical trials.
Prof Sharif is Clinical Director and Advisory Board member for BioInnovate Ireland. He is also serves as a board and faculty member for the Resistant Hypertension Course hosted by EuroPCR, the First Centre of Excellence (CoE) for renal artery denervation training in United Kingdom and Ireland.
Job Titles:
- Member of the Steering Committee
- Non - Executive Director
- Professor in Biomedical Engineering at the National University of Ireland Galway
Professor Mark Bruzzi is a Professor in Biomedical Engineering at the National University of Ireland Galway and is also the Director and co-founder of the BioInnovate Ireland medical device innovation programme. BioInnovate Ireland is a multidisciplinary programme focusing on medical device product development from clinical needs identification, market validation, prototype development and business planning. Mark also is supporting the development of a number of innovative medical technologies He has over 50 journal and conference publications, seven patent applications, 3 licensed technologies and serves as an advisor to several medical device start-ups.
Job Titles:
- Executive Director
- Director of the Translational Medical Device Lab at NUI Galway
- Steering Committee ( Chair )
Dr. Martin O'Halloran is Director of the Translational Medical Device Lab at NUI Galway, the first medical device lab in Ireland to be embedded in a regional hospital and co-located with a clinical trials facility. Dr. O'Halloran is also a non-executive director of the BioInnovate Programme (awarded IMDA's Best Academic MedTech Programme in Ireland 2016) based at NUI Galway. Originally qualifying as an engineer, he re-trained in clinical research to ensure his lab-based research could have a clear and tangible impact on patient care. In 2011, he was the youngest-ever successful co-proposer of a European COST Action (entitled "MiMED"), and is now leading a network of over 180 medical device researchers from 24 countries, focused on the clinical translation and commercialisation of medical devices in Europe. The quality of his research has been recognised both nationally and internationally, and in the last 4 years was awarded: Engineers Ireland Chartered Engineer of the Year 2014, SFI's Early Career Researcher of the Year 2016, and the IRC's inaugural Researcher of the Year 2017. He has also secured 4 grants from the European Research Council, one each year from 2014-2018, and currently leads a team of 25 researchers developing a wide range of diagnostic and therapeutic technologies. Through his medical device work, he has been co-inventor on 7 patents, two of which have already been licensed to Irish medical device companies.
Job Titles:
- Member of the Advisory Board
- Dean of Science and Engineering, University of Galway
Job Titles:
- Member of the Advisory Board
- CEO, Regatta Medical